Ca125 KELIM as a Potential Tool for Predicting Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Benefit at Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer—A Propensity Score–Matched Analysis
Journal of Surgical Oncology · 2026-07 · 134 (1) · 56-64
DOI: 10.1002/jso.70275 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 27.04.2026. Verfasst von Snita Sinukumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Jehangir Hospital, Pune, India. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Ovarian Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, CA-125 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
The aim of the study was to explore the role of KELIM as a potential clinical biomarker to help select patients who would benefit with the addition of Hyperthermic intraperitoneal chemotherapy(HIPEC) at interval cytoreductive surgery following neoadjuvant chemotherapy.
Methods
This was a multi‐institutional, retrospective observational study of 265 patients with Stage IIIC and Stage IV A high grade serous epithelial ovarian cancer who had undergone interval cytoreductive surgery following neoadjuvant chemotherapy. Propensity score matching was performed to reduce confounding by indication for HIPEC. Matching variables were age, FIGO stage, surgical PCI, and NACT cycles. Univariable and multivariable cox‐regression models were created to assess predictors of survival. Survivals were analysed using Kaplan‐Meier curves.
Results
The median OS and median DFS of patients with Low KELIM score and who received HIPEC was 38 months and 18.9 months respectively as compared to Median OS = NR and DFS of 39.7 months respectively in patients with a high KELIM score who received HIPEC. Patients with low KELIM did worse with the addition of HIPEC (3 year OS‐61%, DFS 15%) as compared to patients with High KELIM and HIPEC (3 year OS 90%, DFS‐ 54%).
Conclusion
KELIM may help to identify patients who are likely to benefit from the addition of HIPEC at interval cytoreductive surgery. However, these findings require validation in larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Jehangir Hospital, Pune, India.
- GI Surgical Oncology, ACTREC, Tata Memorial Hospital, Mumbai, India.
- Department of Surgical Oncology, MVR, Cancer Center and Research Institute, Calicut, India.
- Thangam Hospital, Namakkal, India.
- Department of Medical Oncology, Jehangir Hospital, Pune, India.
- Shalby Hospital, Ahmedabad, India.
ORCID-Profile: Snita Sinukumar, Dileep Damodaran, Aruna Prabhu, Aditi Bhatt
Zitieren
APA
Sinukumar, S., Kazi, M., Damodaran, D., Prabhu, A., Piplani, S., Naik, S., Sankaralingam, D., & Bhatt, A. (2026). Ca125 KELIM as a Potential Tool for Predicting Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Benefit at Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer—A Propensity Score–Matched Analysis. Journal of Surgical Oncology, 134(1), 56-64. https://doi.org/10.1002/jso.70275
Vancouver
Sinukumar S, Kazi M, Damodaran D, Prabhu A, Piplani S, Naik S, et al. Ca125 KELIM as a Potential Tool for Predicting Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Benefit at Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer—A Propensity Score–Matched Analysis. Journal of Surgical Oncology. 2026;134(1):56-64. doi:10.1002/jso.70275
BibTeX
@article{Sinukumar2026,
author = {Sinukumar, Snita and Kazi, Mufaddal and Damodaran, Dileep and Prabhu, Aruna and Piplani, Sanjay and Naik, Shailesh and Sankaralingam, Deepika and Bhatt, Aditi},
title = {Ca125 KELIM as a Potential Tool for Predicting Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Benefit at Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer—A Propensity Score–Matched Analysis},
journal = {Journal of Surgical Oncology},
year = {2026},
volume = {134},
number = {1},
pages = {56--64},
doi = {10.1002/jso.70275}
}
EUVIMED